HomeCompareANSNF vs JNJ

ANSNF vs JNJ: Dividend Comparison 2026

ANSNF yields 4444.44% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ANSNF wins by $19857738408180.45M in total portfolio value
10 years
ANSNF
ANSNF
● Live price
4444.44%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19857738408180.48M
Annual income
$19,016,069,933,146,186,000.00
Full ANSNF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ANSNF vs JNJ

📍 ANSNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodANSNFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ANSNF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ANSNF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ANSNF
Annual income on $10K today (after 15% tax)
$377,777.78/yr
After 10yr DRIP, annual income (after tax)
$16,163,659,443,174,257,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, ANSNF beats the other by $16,163,659,443,174,253,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ANSNF + JNJ for your $10,000?

ANSNF: 50%JNJ: 50%
100% JNJ50/50100% ANSNF
Portfolio after 10yr
$9928869204090.25M
Annual income
$9,508,034,966,573,095,000.00/yr
Blended yield
95.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ANSNF
No analyst data
Altman Z
14.5
Piotroski
0/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ANSNF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricANSNFJNJ
Forward yield4444.44%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$19857738408180.48M$30.3K
Annual income after 10y$19,016,069,933,146,186,000.00$4,689.40
Total dividends collected$19800558376185.16M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ANSNF vs JNJ ($10,000, DRIP)

YearANSNF PortfolioANSNF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$455,144$444,444.44$10,592$272.30+$444.6KANSNF
2$19,392,277$18,905,272.87$11,289$357.73+$19.38MANSNF
3$773,548,232$752,798,494.96$12,123$472.89+$773.54MANSNF
4$28,891,953,466$28,064,256,857.57$13,141$629.86+$28891.94MANSNF
5$1,010,538,077,568$979,623,687,360.21$14,408$846.81+$1010538.06MANSNF
6$33,103,483,882,921$32,022,208,139,922.89$16,021$1,151.60+$33103483.87MANSNF
7$1,015,787,352,937,823$980,366,625,183,097.90$18,122$1,588.22+$1015787352.92MANSNF
8$29,201,617,438,828,424$28,114,724,971,184,950.00$20,930$2,228.20+$29201617438.81MANSNF
9$786,606,051,433,916,900$755,360,320,774,370,600.00$24,792$3,191.91+$786606051433.89MANSNF
10$19,857,738,408,180,478,000$19,016,069,933,146,186,000.00$30,274$4,689.40+$19857738408180.45MANSNF

ANSNF vs JNJ: Complete Analysis 2026

ANSNFStock

Anson Resources Limited engages in the acquisition, exploration, and development of mineral resources in the United States and Western Australia. The company offers lithium, bromine, caustic soda, boron, and iodine; and zinc, lead, silver, graphite, nickel-cobalt laterite, vanadium, and uranium deposits. Its flagship property is the Paradox Basin Brine project, which covers an area of 95 square kilometers located in the Utah, the United States of America. The company also holds an interest in the base metal projects comprising The Bull project, which covers an area of 82 square kilometers; Ajana/Mary Springs project that covers an area of 222 square kilometers; and Hooley Well project, which covers an area of 154 square kilometers located in Yilgarn Craton, Western Australia. In addition, it holds an interest in the Yellow Cat project that comprises 85 Lode claim, which covers an area of 708 hectares located in Thompson District, Grand County, Utah. The company was formerly known as Mayan Iron Corporation Limited and changed its name to Anson Resources Limited in January 2016. Anson Resources Limited was incorporated in 2009 and is based in West Perth, Australia.

Full ANSNF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ANSNF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ANSNF vs SCHDANSNF vs JEPIANSNF vs OANSNF vs KOANSNF vs MAINANSNF vs ABBVANSNF vs MRKANSNF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.